Rafael M. Couñago

Rafael M. Couñago

SGC UNC

Couñago

Biography

Rafael M. Couñago, PhD, is a Principal Investigator at the Structural Genomics Consortium Chemical Biology Center at the University of North Carolina (SGC-UNC), Chapel Hill. Rafael´s research group at SGC-UNC uses protein biochemistry, structural biology and cell-based assays to illuminate protein function and explore new therapeutic strategies for human diseases. Current research at SGC-UNC is focused on enabling the discovery of new antiviral compounds and realizing SGC´s vision for Target 2035, an open science initiative that aims to create chemical and biological tools for every protein in the human genome with the goal of informing drug discovery (https://www.target2035.net/). Rafael joined SGC-UNC after working as a Principal Investigator at the Center of Medicinal Chemistry at the University of Campinas (UNICAMP), São Paulo, Brazil. Prior to that, Rafael served as Team Leader and CSO at SGC-UNICAMP, and was a post-doctoral researcher at the laboratories of Bostjan Kobe at the University of Queensland, Australia; Kurt Krause at Otago University, New Zealand, and Youssif Shamoo at Rice University, USA. Rafael has a strong track record in recombinant protein production, biochemical and cellular assay development, and structure determination, and has participated in a number of early-stage drug discovery projects in collaboration with both academic and industrial partners

2019

WNT Activates the AAK1 Kinase to Promote Clathrin-Mediated Endocytosis of LRP6 and Establish a Negative Feedback Loop.

Agajanian MJ, Walker MP, Axtman AD, Ruela-de-Sousa RR, Serafin DS, Rabinowitz AD, Graham DM, Ryan MB, Tamir T, Nakamichi Y, Gammons MV, Bennett JM, Couñago RM, Drewry DH, Elkins JM, Gileadi C, Gileadi O, Godoi PH, Kapadia N, Müller S, Santiago AS, Sorrell FJ, Wells CI, Fedorov O, Willson TM, Zuercher WJ, Major MB

Cell Rep. 2019-1-2 . 26(1):79-93.e8 .doi: 10.1016/j.celrep.2018.12.023

PMID: 30605688

2018

Structural Analysis of Inhibitor Binding to CAMKK1 Identifies Features Necessary for Design of Specific Inhibitors.

Santiago ADS, Couñago RM, Ramos PZ, Godoi PHC, Massirer KB, Gileadi O, Elkins JM

Sci Rep. 2018-10-4 . 8(1):14800 .doi: 10.1038/s41598-018-33043-4

PMID: 30287839

1,2,6-Thiadiazinones as Novel Narrow Spectrum Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) Inhibitors.

Asquith CRM, Godoi PH, Couñago RM, Laitinen T, Scott JW, Langendorf CG, Oakhill JS, Drewry DH, Zuercher WJ, Koutentis PA, Willson TM, Kalogirou AS

Molecules. 2018-5-19 . 23(5): .doi: 10.3390/molecules23051221

PMID: 29783765

Cloning, expression and purification of kinase domains of cacao PR-1 receptor-like kinases.

Tosarini TR, Ramos PZ, de Souza GP, Baroni RM, Massirer KB, Couñago RM, Mondego JMC

Protein Expr. Purif.. 2018-1-19 . .doi: 10.1016/j.pep.2018.01.004

PMID: 29360581

2017

Structural characterization of human Vaccinia-Related Kinases (VRK) bound to small-molecule inhibitors identifies different P-loop conformations.

Couñago RM, Allerston CK, Savitsky P, Azevedo H, Godoi PH, Wells CI, Mascarello A, de Souza Gama FH, Massirer KB, Zuercher WJ, Guimarães CRW, Gileadi O

Sci Rep. 2017-8-8 . 7(1):7501 .doi: 10.1038/s41598-017-07755-y

PMID: 28790404

Structural Characterization of Maize SIRK1 Kinase Domain Reveals an Unusual Architecture of the Activation Segment.

Aquino B, Couñago RM, Verza N, Ferreira LM, Massirer KB, Gileadi O, Arruda P

Front Plant Sci. 2017-6-13 . 8:852 .doi: 10.3389/fpls.2017.00852

PMID: 28603531